The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Phase 2 NFKB2 rearrangement-driven MM trial: predictor of sensitivity to PIs?
Sagar Lonial, MD, FACP, Winship Cancer Institute at Emory University, Atlanta, GA, covers the phase 2 trial of ixazomib and dexamethasone vs. ixazomib, dexamethasone and lenalidomide, randomized with NFKB2 rearrangement (NCT02765854). This aimed to use NFKB2 status as a biomarker to predict for sensitivity to proteasome inhibitors (PIs). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
